Published in Clin Exp Immunol on January 01, 1990
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03
FK 506 and autoimmune disease: perspective and prospects. Autoimmunity (1992) 0.85
Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. Clin Exp Immunol (1990) 0.81
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study. Mult Scler Int (2012) 0.78
Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine. Transplant Proc (1993) 0.76
The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. Transplant Proc (1991) 0.75
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity (1994) 0.75
Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology (1968) 24.83
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) (1987) 4.54
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A (1985) 4.19
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol (1987) 3.30
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. Transplant Proc (1987) 2.84
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
FK-506--how much potential? Immunol Today (1989) 2.20
Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation (1987) 2.15
Cyclosporin A and the thymus. Immunopathology. Am J Pathol (1987) 1.65
Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation (1987) 1.65
FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. Transplant Proc (1987) 1.56
Kidney transplantation in the dog receiving FK-506. Transplant Proc (1987) 1.54
Cyclosporine inhibits macrophage-mediated antigen presentation. J Immunol (1986) 1.27
Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation (1989) 1.23
Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation (1989) 1.22
Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation. J Immunol (1986) 1.22
Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation (1988) 1.21
Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol (1988) 1.15
Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol (1988) 0.99
Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation (1989) 0.98
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology (1986) 0.95
Effects of FK-506 on collagen arthritis in mice. Transplant Proc (1989) 0.91
Cyclosporine affects the function of antigen-presenting cells. Immunology (1986) 0.91
Inhibition of human monocyte antigen presentation, but not HLA-DR expression, by cyclosporine. Transplantation (1987) 0.89
Effect of cyclosporine on the antigen-presenting function of human and murine accessory cells. Transplantation (1988) 0.82
The impaired ability of human monocytes to stimulate autologous and allogeneic mixed lymphocyte reactions after exposure to cyclosporine. Associated alterations of HLA-DR expression and physical characteristics of monocytes. Transplantation (1985) 0.82
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg (2001) 3.49
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
FK 506: an immunosuppressant for the 1990s? Lancet (1991) 2.80
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
FK-506--how much potential? Immunol Today (1989) 2.20
MediCaring: development and test marketing of a supportive care benefit for older people. J Am Geriatr Soc (1999) 2.03
Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines. Immunology (1983) 1.99
Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol (2001) 1.95
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation (1995) 1.63
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol (1996) 1.53
Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51
Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood (2001) 1.47
Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J Immunol (2000) 1.47
Pregnancy specific beta1-glycoprotein--a product of the syncytiotrophoblast. Experientia (1976) 1.46
Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal. Transplantation (1981) 1.38
Toxicity of the immune suppressant cyclosporin A in the rat. J Pathol (1982) 1.38
Mediastinitis and long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg (2000) 1.37
Immunobiology of cyclosporin A--a review. Aust J Exp Biol Med Sci (1983) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29
Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs. Immunology (1983) 1.27
Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol (1994) 1.25
Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant (2006) 1.24
Fundamental Ca2+ signaling mechanisms in mouse dendritic cells: CRAC is the major Ca2+ entry pathway. J Immunol (2001) 1.23
Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation (1998) 1.22
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Cyclosporin: use outside transplantation. BMJ (1991) 1.22
Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol (2001) 1.21
Evaluation of carrageenan as an immunosuppressive agent and mediator of intravascular coagulation. Biomedicine (1976) 1.20
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Biological and clinical significance of pregnancy-associated alpha2-glycorprotein (alpha/-PAG)-a review. Invest Cell Pathol (1981) 1.18
Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release (2008) 1.17
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation (1997) 1.17
Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology (1995) 1.17
Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation (1994) 1.16
Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol (1997) 1.16
New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant (2008) 1.14
Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions (1984) 1.14
Experimental cyclosporin A nephrotoxicity. Br J Exp Pathol (1982) 1.12
Deep sequencing analysis of defective genomes of parainfluenza virus 5 and their role in interferon induction. J Virol (2013) 1.12
Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther (2000) 1.10
Cyclosporine-induced fetotoxicity in the rat. Transplantation (1985) 1.10
Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation (1995) 1.10
Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant (2008) 1.10
Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation (2001) 1.09
Major histocompatibility complex class II antigen (HLA-DR, DQ and DP) expression in human fetal skin. Tissue Antigens (1986) 1.09
Toxicity of various carrageenans in the mouse. Br J Exp Pathol (1976) 1.09
FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplant Proc (1991) 1.09
Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol (2001) 1.08
Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol (1998) 1.07
Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol (1991) 1.07
Effect of carrageenan on activity of the mononuclear phagocyte system in the mouse. Br J Exp Pathol (1978) 1.07
Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells. J Immunol (2000) 1.07
Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation (1999) 1.05
Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol (1997) 1.05
Failure to activate the IFN-β promoter by a paramyxovirus lacking an interferon antagonist. Virology (2011) 1.04
Serum cyclosporin levels, hepatic drug metabolism and renal tubulotoxicity. Biochem Pharmacol (1984) 1.03
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03
FK-506 enters the clinic. Immunol Today (1990) 1.03
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 1.01
Acetone production by methylobacteria. Arch Microbiol (1976) 0.99
Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol (1988) 0.99
Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice. Br J Cancer (1979) 0.98
Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation (1989) 0.98
Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse. Clin Exp Immunol (1983) 0.98
Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation (1998) 0.97
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes. Immunology (1987) 0.97
The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation (1993) 0.97
Potentiation of tumour growth by carrageenan. Transplantation (1977) 0.97
Dendritic cells and tolerance induction. Clin Exp Immunol (1996) 0.97
Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation (1996) 0.96
Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation (1996) 0.96
In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol (1997) 0.96
Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J Immunol (2001) 0.96
Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. Transplant Proc (1992) 0.96
Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc (1998) 0.95
A toxicological study in rats receiving immunotherapeutic doses of cyclosporin A. Transplantation (1981) 0.95
Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology (1986) 0.95
Research in complementary medicine is essential. BMJ (2001) 0.95
Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc (1991) 0.95
Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks. Br J Exp Pathol (1983) 0.94
Rosette inhibition levels during early human gestation. J Reprod Immunol (1980) 0.94
Detection of pregnancy associated alpha 2-glycoprotein (alpha 2-PAG), an immunosuppressive agent, in IgA producing plasma cells and in body secretions. Clin Exp Immunol (1983) 0.94
Potential of tolerogenic dendritic cells for transplantation. Semin Immunol (2001) 0.93
Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Transplant Proc (1999) 0.93
Effects of the antiprotease Trasylol on peripheral blood leucocytes. Experientia (1978) 0.93
Preferential induction of Th1 responses by functionally mature hepatic (CD8alpha- and CD8alpha+) dendritic cells: association with conversion from liver transplant tolerance to acute rejection. Transplantation (2000) 0.92
Study of pregnancy-associated alpha2-glycoprotein in relation to populations of human blood leucocytes. Int Arch Allergy Appl Immunol (1979) 0.92